Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania

Psychopharmacology Bulletin

Volumn 32, Issue 1, 1996, Pages 55-61

  Sajatovic, Martha ^a,b   DiGiovanni, Sue Kim ^a   Bastani, Bijan ^a,b   Hattab, Helen ^a,b   Ramirez, Luis F ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

antipsychotic medication; bipolar disorder; mania; risperidone; schizoaffective disorder

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORAL HYDRATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; FLUPHENAZINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; VALPROIC ACID;

ADULT; AKATHISIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MUSCLE RIGIDITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SEDATION;

ADULT; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; FEMALE; HUMANS; MALE; PILOT PROJECTS; RISPERIDONE;

EID: 0029948060     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: The Association, 1994.
2. Borison, RL; Pathiraja, AP; Diamond, BI; and Meibach, BC. Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol. Bull. 28(2):213-218, 1992.
3. 2 antagonist risperidone (R 64, 766), in the treatment of chronic psychosis. An open dose-finding study. Schizophr. Res. 2:411-415, 1989.
4. Chouinard, G; Jones, B; Remington, G; Bloom, D; Addington, D; MacEwan, W; Labelle, A; Beauclair, L; and Arnott, W. A Canadian multi-center placebo controlled study of fixed doses of risperidone and haloperidol in treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:25-40, 1993.
5. Cohen, S, and Underwood, MT. The use of clozapine in a mentally retarded and aggressive population. J. Clin. Psychiatry 55(10):440-444, 1994.
6. Coppen, A; Ghose, K; Rao, VR; and Peet, M. Mianserin in the prophylactic treatment of bipolar affective illness. Int. Pharmacopsychiatry 12:95-99, 1987.
7. Dwight, MM; Keck, PE; Stanton, SP: Strawkowski, SM; and McElroy, SL. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 344:554-555, 1994.
8. Gelders, YG; Heylen, SL; Vanden Bussche, G; Reyntjens, AJ; and Janssen, PA. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 23(5):206-211, 1990.
9. Gerlach, J. New antipsychotics: Classification, efficacy and adverse effects. Schizophr. Bull. 17(2):280-309, 1991.
10. Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM)76-338. Rockville, MD: National Institute of Mental Health, 1976.
11. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23:56-62, 1960.
12. Hillert, A; Maier, W; Wetzel, H; and Benkert, O. Risperidone in the treatment of disorders with combined psychotic and depressive syndromes-A functional approach. Pharmacopsychiatry (25):213-217, 1992.
13. 2 antagonist properties. J. Pharmacol. Exp. Ther. 244(2):685-693, 1988.
14. Kay, SR; Fiszbein, A; and Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:261-276, 1987.
15. Kimmel, SE; Calabrese, JR; Woyshville, MJ; and Meltzer, HY. Clozapine in treatment-refractory mood disorders. J. Clin. Psychiatry 55 (Suppl. B):91-93, 1994.
16. Livingston, MG. Risperidone. Lancet 343:457-460, 1994.
17. Marder, SR, and Meibach, RC. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151:825-835, 1994.
18. McElroy, SL; Dessain, EC; Pope, HG; Cole, JO; Keck, PE; Frankenberg, FR; Aizley, HG; and O'Brien, S. Clozapine in the treatment of psychotic mood disorder, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry 52:411-414, 1991.
19. Meltzer, HY, and Lowy, MI. The serotonin hypothesis of depression. In: Meltzer, HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987. pp. 513-526.
20. Mesotten, F; Suy, E; Pietquin, M; Burton, P; Heylen, S; and Gelders, Y. Therapeutic effect and safety of increasing doses of risperidone (R 64, 766) in psychotic patients. Psychopharmacology 99(4):445-449, 1989.
21. Miller, F, and Menninger, J. Correlation of neuroleptic dose and neurotoxicity in patients given lithium and a neuroleptic. Hosp. Community Psychiatry 38(11): 1219-1221, 1987.
22. Moller, HJ; Pelzer, E; Kissling, W; Riehl, T; and Wernicke, T. Efficacy and tolerability of a new antipsychotic compound (risperidone); results of a pilot study. Pharmacopsychiatry 24(6): 185-189, 1991.
23. Monsma, FJ; Shen, Y; Ward, RP; Hamblin, MW; and Sibley, DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43:320-327, 1993.
24. Mukherjee, S; Rosen, A; Caracci, C; and Shukla, S. Persistent tardive dyskinesia in bipolar patients. Arch. Gen. Psychiatry 43:342-346, 1986.
25. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
26. Overall, JE, and Gorham, D. The Brief Psychiatric Rating Scale. Psychol. Rep. 10:799-812, 1962.
27. Prien, RF; Caffey, EM; and Klett, CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania: Report of The Veterans Administration and National Institute Study Group. Arch. Gen. Psychiatry 26:146-153, 1972.
28. Ratey, J; Leverom, C; Kilmer, D; Gutheil, C; and Swartz, B. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J. Clin. Psychiatry 32:270-280, 1993.
29. 1c receptors. J. Pharmacol. Exp. Ther. 260:1361-1365, 1992.
30. 7) receptors. J. Pharmacol. Exp. Ther. 268:1403-1410, 1994.
31. Sajatovic, M; Ramirez, L; Kenny, J; and Meltzer, HY. The use of clozapine in borderline intellectual functioning and mentally retarded schizophrenic patients. Compr. Psychiatry 35(1):29-33, 1994.
32. 7 serotonin receptor subtype. J. Biol. Chemistry 268:18200-18204, 1993.
33. Simpson, G, and Angus, J. Drug induced extrapyramidal disorders. Acta Psychiatr. Scand. (Suppl. 212), 1970.
34. Simpson, GM; Lee, JH; and Shrivastava, RK. Clozapine in tardive dyskinesia. Psychopharmacology (Berl.) 59:105-112, 1978.
35. Sturdy, JL, and Mahapatra, SB. Mianserin and mania. Br. J. Psychiatry 153:269-270, 1988.
36. Suppes, T; McElroy, SC; Gilbert, J; Dessain, EC: and Cole, JO. Clozapine in the treatment of dysphoric mania. Biol. Psychiatry 32:270-280, 1992.
37. Tang, SW, and Helmeste, DM. Serotonin receptors in affective disorders. In: Senka, LT. Receptors and Ligands in Psychiatry. Vol. 4. Cambridge, England: Cambridge University Press, 1988. pp. 245-270.
38. Tohen, M; Zarate, C; Centorrino, F; Hegarty, J; and Froeschl, M. "Risperidone in the Treatment of Mania." Poster presented at the 35th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Orlando, FL, June 1995.
39. Vanden Borre, R; Vermote, R; Buttiens, M; Thiry, P; Dierick, G; Geutjens, J; Sieben, G; and Heylen, S. Risperidone as add-on therapy in behavioral disturbances in mental retardation; a double-blind placebo-controlled crossover study. Acta Psychiatr. Scand. 87(3): 167-171, 1993.
40. Young, RC; Biggs, JT; Ziegler, VE; and Meyer, DA. A rating scale for mania: Reliability, validity, and sensitivity. Br. J. Psychiatry 133:429-435, 1978.